- With thee approval from NICE, Ajovy can be used for treating prophylaxis of migraine in adults with chronic migraine unresponsive to at least three prior preventive treatments.
- The decision from NICE can definitely help many people as Migraine therapies are limited in England and Wales.
The National Institute for Health and Care Excellence (NICE) has approved Ajovy (manufactured by Teva) for use in the treatment for prophylaxis of migraine in adults suffering from chronic migraine. However, according to the current order, the Ajovy can used for treating only those adults who have not responded to at least three prior preventive treatments.
The anti-Calcitonin gene-related peptide (CGRP) preventive therapy is the first of-its-kind to be approved and recommended by NICE. It offers monthly or quarterly dosing options. Once trained by doctors to use it, patients can also self-inject it.
Calling the decision of NICE a “fantastic news,” Dr Mark Weatherall, president of the British Association for the Study of Headache, said:
“Anyone who looks after people with chronic migraine understands just how debilitating this neurological disorder can be. We have waited a long time for this new class of drug to be made available in the NHS, but now that we can prescribe fremanezumab, I am excited to see what a difference it will make to the lives of many of my worst affected patients.”
Seriousness Of Migraine
The migraine prevention therapies in England and Wales being limited currently. None of the commonly used treatments were developed specifically to target the molecular pathways of migraine. These treatments included anti-depressants, anti-epileptics, beta blockers and botulinum toxin injections.